Acadia Pharmaceuticals Inc. (ACAD)
NASDAQ
Real-time Data
01:30 PM
Day's Range
19.3252 wk Range
19.32Overview - ACAD - Acadia Pharmaceuticals Inc.
Key Statistics
Valuation
Enterprise Value
2.55B
P/E (Trailing)
‪8.94‬
P/E (Forward)
‪22.45‬
PEG Ratio
‪0.71‬
Price / Sales (TTM)
‪3.01‬
Price / Book
‪2.62‬
EV / EBITDA
‪25.96‬
Profitability
Gross Margin
‪90.80%‬
Profit Margin
‪33.41%‬
Operating Margin
‪12.28%‬
Return on Assets
‪3.63%‬
Return on Equity
‪35.74%‬
Ownership
Shares Outstanding
172.13M
Float
128.35M
Short % of Shares Outstanding
‪8.87%‬
Held by Insiders
‪0.33%‬
Held by Institutions
‪99.64%‬
Price stats
Beta
‪0.85‬
50-Day Avg
‪27.05‬
200-Day Avg
‪24.43‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
20 analysts
Average price target
‪$ 33.85‬Shariah Compliance
Report Date: Feb 16, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - ACAD - Acadia Pharmaceuticals Inc.
Peers - ACAD - Acadia Pharmaceuticals Inc.
Peer Comparison
Compared with companies in Biotechnology listed on NASDAQ.
- ACADNASDAQACADIA Pharmaceuticals Inc3.43BMarket Cap-8.22%52-week change8.95P/E (Trailing)‪33.41%‬Profit Margin
- ARGXNASDAQArgenx SE57.50BMarket Cap+14.28%52-week change34.96P/E (Trailing)‪32.26%‬Profit Margin
- ALNYNASDAQAlnylam Pharmaceuticals, Inc.29.40BMarket Cap-105.72%52-week change38.35P/E (Trailing)‪16.12%‬Profit Margin
- BNTXNASDAQBioNTech SE American Depositary Share24.34BMarket Cap-8.52%52-week change160.80P/E (Trailing)‪-63.63%‬Profit Margin
- ASNDNASDAQAscendis Pharma A/S14.99BMarket Cap+7.48%52-week change17.72P/E (Trailing)‪70.84%‬Profit Margin
- BBIONASDAQBridgeBio Pharma Inc.13.14BMarket Cap+18.80%52-week change-17.80P/E (Trailing)‪-97.02%‬Profit Margin
- BMRNNASDAQBioMarin Pharmaceutical Inc.11.06BMarket Cap+2.75%52-week change154.54P/E (Trailing)‪2.14%‬Profit Margin
Profile Summary - ACAD - Acadia Pharmaceuticals Inc.
About
Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing medicines for central nervous system disorders and rare diseases. The company’s commercial portfolio includes treatments for Parkinson’s disease psychosis and Rett syndrome, reflecting its emphasis on neuropsychiatric…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
